Stock Analiz

Aligos Therapeutics, Inc. ALGS

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2020 · data as of November 13, 2026

$2.10Market cap $13M
Open the interactive analysis →

Aligos Therapeutics, Inc. (ALGS) is a healthcare company listed in the US with a market value of about $13M. In the twelve months to September 30, 2026 it had revenue of $6M and net income of -$66M, a net margin of -1137.2%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -76%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 91% below the current price.

About Aligos Therapeutics

Aligos Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2020. It was profitable in 0 of the last 7 years in our data. Its share count rose by 480% over three years (dilution for shareholders). It spends 3177% of revenue on research and development.

Score: 0.8 / 5

Value0/5
Future growth2/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S2.3
P/B1.2
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price−91%

Growth and quality

Revenue growth (1 yr)-39.5%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-2052.2%
ROIC (5-yr avg.)-75.9%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 7 years

Fiscal yearTTM2025202420232022202120202019
Revenue$6M$2M$4M$6M$0$0$0—
Net income-$66M-$24M-$131M-$88M-$96M-$128M-$109M-$52M
Free cash flow——-$81M-$79M-$80M-$117M-$76M-$50M
EPS (diluted)$-6.45$-2.45$-20.94$-34.20$-56.40$-80.72$-272.49$-652.77
Net margin-1137.2%-1106.7%-3633.7%-1416.2%————
ROIC—-118.5%—-67.6%-66.4%-51.0%-33.2%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Aligos Therapeutics stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 91% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Aligos Therapeutics pay a dividend?

Not currently.

Is Aligos Therapeutics a good stock to buy?

We do not give buy or sell advice. Aligos Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.